PGP and myeloid sarcoma: Based on our results, the prime target for the treatment of MS is affecting P-gp on DCs by immunotherapy, as DCs are ideal tools for immunotherapeutic strategies due to their intrinsic capacity to efficiently present antigens to T cells thereby regulating T cell responses.